Form 4: Marinus Pharmaceuticals CEO Sells Shares to Cover Tax Obligations

Marinus Pharmaceuticals CEO Scott Braunstein sold 12,145 shares of common stock on August 5, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

• Scott Braunstein, the Chairman and CEO of Marinus Pharmaceuticals, Inc., sold 12,145 shares of common stock on August 5, 2024.
• The sale was executed at a weighted-average price of $1.13 per share, with individual transactions ranging from $1.11 to $1.15.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 16, 2022.
• The purpose of the sale was to cover tax obligations associated with the vesting of restricted stock units.
• Following the transaction, Braunstein directly owns 298,667 shares of Marinus Pharmaceuticals.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The sale is for tax purposes under a pre-arranged plan, which is a common and expected practice. The CEO still holds a significant number of shares.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was planned and not based on immediate market conditions.
• The CEO still holds a significant number of shares (298,667) after the sale, suggesting continued alignment with the company's performance.

Industry Context

Sales of shares by company executives are a common occurrence, often related to personal financial planning or tax obligations. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Stakeholder Impact

• The sale could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sale mitigates this concern.

Key Dates

Keywords

Marinus Pharmaceuticals, MRNS, Scott Braunstein, stock sale, Form 4, Rule 10b5-1, restricted stock units, tax obligations